cholestenone 5 alpha reductase

Summary

Summary: An oxidoreductase that catalyzes the conversion of compounds that contain 5-alpha-cholestan-3-one into the cholest-4-en-3-one derivative. It plays an important role in the conversion of TESTOSTERONE into DIHYDROTESTOSTERONE and PROGESTERONE into DIHYDROPROGESTERONE.

Top Publications

  1. ncbi Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor
    Richard V Clark
    Clinical Pharmacology, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina 27709, USA
    J Clin Endocrinol Metab 89:2179-84. 2004
  2. ncbi Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways
    A G Latil
    Center for Research into Prostate Pathologies, Evry, France
    Cancer 92:1130-7. 2001
  3. ncbi Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss
    Jeremy W Tomlinson
    Division of Medical Sciences, Institute of Biomedical Research, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK
    Diabetes 57:1536-43. 2008
  4. ncbi Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline
    Barnett S Kramer
    National Institutes of Health, Bethesda, MD, USA
    J Urol 181:1642-57. 2009
  5. ncbi Increased A-ring reduction of glucocorticoids in obese Zucker rats: effects of insulin sensitization
    Dawn E W Livingstone
    Endocrinology Unit, University of Edinburgh, Queen s Medical Research Institute, Edinburgh, UK
    Obes Res 13:1523-6. 2005
  6. ncbi The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations
    Leonard S Marks
    Department of Urology, School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    J Urol 176:868-74. 2006
  7. ncbi Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study
    A W Hsing
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20852 7234, USA
    Cancer Epidemiol Biomarkers Prev 10:1077-82. 2001
  8. ncbi V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression
    R K Nam
    Division of Urology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Urology 57:199-204. 2001
  9. ncbi An update on the use of 5alpha-reductase inhibitors
    Charlotte L Foley
    Institute of Urology and Nephrology, UCL, London, UK
    Drugs Today (Barc) 40:213-23. 2004
  10. ncbi Evaluation of cell permeation of a potent 5alpha-reductase inhibitor using MALDI-TOF MS
    Sonal Mathur
    Pharmaceutical and Medicinal Chemistry, Saarland University, D 66041 Saarbruecken, Germany
    J Enzyme Inhib Med Chem 19:425-9. 2004

Detail Information

Publications233 found, 100 shown here

  1. ncbi Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor
    Richard V Clark
    Clinical Pharmacology, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina 27709, USA
    J Clin Endocrinol Metab 89:2179-84. 2004
    ..3% suppression observed with 5 mg finasteride. Mean testosterone levels increased but remained in the normal range for all treatment groups. Dutasteride appeared to be well tolerated with an adverse event profile similar to placebo...
  2. ncbi Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways
    A G Latil
    Center for Research into Prostate Pathologies, Evry, France
    Cancer 92:1130-7. 2001
    ..The authors evaluated the association between polymorphisms in genes involved in the androgen biosynthesis and metabolism pathway and the risk of prostate carcinoma...
  3. ncbi Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss
    Jeremy W Tomlinson
    Division of Medical Sciences, Institute of Biomedical Research, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK
    Diabetes 57:1536-43. 2008
    ..We have assessed the impact of weight loss on glucocorticoid secretion and metabolism (notably 11beta-hydroxysteroid dehydrogenase type 1 and 5alpha-reductase [5alphaR] activity) and insulin sensitivity...
  4. ncbi Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline
    Barnett S Kramer
    National Institutes of Health, Bethesda, MD, USA
    J Urol 181:1642-57. 2009
    ..To develop an evidence-based guideline on the use of 5-alpha-reductase inhibitors (5-ARIs) for prostate cancer chemoprevention...
  5. ncbi Increased A-ring reduction of glucocorticoids in obese Zucker rats: effects of insulin sensitization
    Dawn E W Livingstone
    Endocrinology Unit, University of Edinburgh, Queen s Medical Research Institute, Edinburgh, UK
    Obes Res 13:1523-6. 2005
    ..Here we characterize hepatic 5alpha- and 5beta-reductase in obese rats and their responses to insulin sensitization...
  6. ncbi The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations
    Leonard S Marks
    Department of Urology, School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    J Urol 176:868-74. 2006
    ....
  7. ncbi Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study
    A W Hsing
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20852 7234, USA
    Cancer Epidemiol Biomarkers Prev 10:1077-82. 2001
    ....
  8. ncbi V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression
    R K Nam
    Division of Urology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Urology 57:199-204. 2001
    ..We examined whether this polymorphism predicts the presence of prostate cancer in 320 men without cancer who underwent biopsy and cancer progression in 318 men who underwent radical prostatectomy...
  9. ncbi An update on the use of 5alpha-reductase inhibitors
    Charlotte L Foley
    Institute of Urology and Nephrology, UCL, London, UK
    Drugs Today (Barc) 40:213-23. 2004
    ..Wider applications of 5alpha-reductase inhibitors are also emerging, though their perhaps most important new role as chemopreventive agents remains unclear...
  10. ncbi Evaluation of cell permeation of a potent 5alpha-reductase inhibitor using MALDI-TOF MS
    Sonal Mathur
    Pharmaceutical and Medicinal Chemistry, Saarland University, D 66041 Saarbruecken, Germany
    J Enzyme Inhib Med Chem 19:425-9. 2004
    ..These results suggest that the in vivo activity of 1 might be increased by the use of its methyl ester prodrug 1a...
  11. ncbi Proscar and propecia--a therapeutic perspective
    Robert Palusinski
    J Clin Endocrinol Metab 89:6359. 2004
  12. ncbi Genetic polymorphisms in the androgen receptor and type II 5 alpha-reductase genes in prostate enlargement
    A Shibata
    Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California, USA
    J Urol 166:1560-4. 2001
    ....
  13. ncbi Dietary soy-phytoestrogens decrease testosterone levels and prostate weight without altering LH, prostate 5alpha-reductase or testicular steroidogenic acute regulatory peptide levels in adult male Sprague-Dawley rats
    K S Weber
    Neuroscience Center, Brigham Young University, Provo, Utah 86402, USA
    J Endocrinol 170:591-9. 2001
    ....
  14. ncbi Steroid hormone influence on brain calbindin-D(28K) in male prepubertal and ovariectomized rats
    E B Stuart
    Neuroscience Center, 633 WIDB, Brigham Young University, Provo, UT 84602, USA
    Brain Res Dev Brain Res 129:125-33. 2001
    ....
  15. ncbi Stable expression of the human 5alpha-reductase isoenzymes type I and type II in HEK293 cells to identify dual and selective inhibitors
    W Reichert
    Fachrichtung 12.1 Pharmazeutische und Medizinische Chemie, , , Germany
    J Enzyme Inhib 16:47-53. 2001
    ..Reaction products were quantified by a HPLC reversed phase technique. Using the new cell assays, selective as well as novel dual 5alpha-reductase inhibitors with IC50 values between 1.0 and 2.5 microM were identified...
  16. pmc The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men
    John K Amory
    Department of Medicine, University of Washington, Seattle, Washington, USA
    J Urol 179:2333-8. 2008
    ..Because androgens affect bone, lipids, hematopoiesis, prostate and sexual function, we determined the impact of 5alpha-reductase inhibitors on these end points...
  17. ncbi Sebocytes are the key regulators of androgen homeostasis in human skin
    M Fritsch
    Department of Dermatology, University Medical Center Benjamin Franklin, The Free University of Berlin, Berlin, Germany
    J Invest Dermatol 116:793-800. 2001
    ..Sebocytes are able to synthesize testosterone from adrenal precursors and to inactivate it in order to maintain androgen homeostasis, whereas keratinocytes are responsible for androgen degradation...
  18. ncbi Inhibition of 5alpha-reductase blocks prostate effects of testosterone without blocking anabolic effects
    Stephen E Borst
    Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, Florida, USA
    Am J Physiol Endocrinol Metab 288:E222-7. 2005
    ..0001). This study demonstrates that 5alpha-reductase inhibitors may block the undesirable effects of T on the prostate, without blocking the desirable anabolic effects of T on muscle, bone, and fat...
  19. ncbi Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride
    Lucy J Schmidt
    Department of Urology Research, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Androl 25:944-53. 2004
    ..1. Collectively, our findings delineate the cellular and molecular effects of dutasteride in androgen-responsive PCa cells in vitro and may lead to its better therapeutic and chemopreventive use in PCa...
  20. ncbi Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line
    Jesús M Golbano
    Servicio de Urologia, Hospital General Universitario de Guadalajara, Guadalajara, Spain
    Int J Oncol 32:919-24. 2008
    ..These findings suggest that finasteride induces apoptosis in LNCaP cells via proteins of the Bcl-2 and caspase family...
  21. ncbi Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds
    I P Nnane
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore 21201, USA
    Endocrinology 140:2891-7. 1999
    ..Although future improvements in their bioavailability are necessary, these novel steroidal compounds show promise as potential agents for reducing T and DHT levels in patients with androgen dependent diseases...
  22. ncbi Molecular analysis of 5alpha-reductase type 2 gene in eight unrelated egyptian children with suspected 5alpha-reductase deficiency: prevalence of the G34R mutation
    Inas Mazen
    The National Research Center, Cairo University, Cairo, Egypt
    Clin Endocrinol (Oxf) 58:627-31. 2003
    ..Analysis of the 5alpha-reductase type 2 (SRD5A2) gene in Egyptian patients with suspected 5alpha-reductase (5alphaR) deficiency...
  23. ncbi Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population
    Zhenhua Li
    Department of Urology, Akita University School of Medicine, Akita, Japan
    J Urol 169:2378-81. 2003
    ..We explored the association among these polymorphisms and the risk of prostate cancer or benign prostatic hyperplasia (BPH) in a Japanese population...
  24. ncbi Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor
    Stephen V Frye
    Department of High Throughput Chemistry, Discovery Research, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina 27709, USA
    Curr Top Med Chem 6:405-21. 2006
    ..The connections between preclinical drug design and clinical outcomes during the discovery and development of dutasteride are exemplified...
  25. ncbi 5 alpha-reductase-catalyzed conversion of testosterone to dihydrotestosterone is increased in prostatic adenocarcinoma cells: suppression by 15-lipoxygenase metabolites of gamma-linolenic and eicosapentaenoic acids
    Hung Pham
    Department of Dermatology, School of Medicine, University of California at Davis, TB 192, One Shields Avenue, 95616, USA
    J Steroid Biochem Mol Biol 82:393-400. 2002
    ..Taken together, the study underscores the biological importance of 15-lipoxygenase metabolites of polyunsaturated fatty acids (PUFAs) in androgen metabolism...
  26. ncbi Micropenis: an animal model and its human correlates
    Douglas A Husmann
    Division of Pediatric Urology, Mayo Clinic, Rochester, Minnesota, USA
    Adv Exp Med Biol 511:41-54; discussion 54-6. 2002
  27. ncbi Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism
    Qing Ji
    Division of Gastrointestinal and Liver Disease, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Prostate 54:275-89. 2003
    ..Functional activity and regulation of AKR1C2, a 3 alpha-hydroxysteroid dehydrogenase (HSD) type III, was also assessed in prostate cancer cell lines...
  28. ncbi [Enzyme inhibition in the drug therapy of benign prostatic hyperplasia]
    J Drsata
    Farmaceutická fakulta UK, Hradec Kralove
    Cas Lek Cesk 141:630-5. 2002
    ..Inhibition of the "aromatase" complex, which catalyzes transformation of androgens to estrogens, may contribute to the complexity of phytotherapeutic effects...
  29. ncbi Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome
    Martin Fassnacht
    Department of Medicine, Endocrine and Diabetes Unit, University of Wurzburg, 97080 Wurzburg, Germany
    J Clin Endocrinol Metab 88:2760-6. 2003
    ..05). Taken together, these data indicate enhanced peripheral 5 alpha-reductase activity in PCOS. Thus, not only ovary and adrenal, but also liver and peripheral target tissues, significantly contribute to steroid alterations in PCOS...
  30. ncbi Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate
    Abdel Rahmene Azzouzi
    CeRePP EA3104, Universite Paris VII, Genopole, 4 rue Pierre Fontaine, Evry F 91000, France
    Eur J Endocrinol 147:479-84. 2002
    ..We have evaluated the correlation between specific genotypes in androgen- and oestrogen-regulating genes (AR, SRD5A2, CYP17 and CYP19), and age-related prostatic changes...
  31. ncbi Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma
    Jun Luo
    Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Prostate 57:134-9. 2003
    ..The therapeutic influence of SRD5A2 inhibitor finasteride on prostate cancer is currently unknown. The direction and extent of changes in SRD5A2 expression in disease tissues is a relevant issue in this regard...
  32. ncbi Stable expression of human 5alpha-reductase type II in COS1 cells due to chromosomal gene integration: a novel tool for inhibitor identification
    W Reichert
    FR 8.5 Pharmaceutical and Medicinal Chemistry, University of the Saarland, P.O. Box 151150, D-66041, , Germany
    J Steroid Biochem Mol Biol 78:275-84. 2001
    ..The newly established cell line was used for testing novel compounds on their inhibitory effect on human 5alpha-reductase type II. Using this whole cell assay, inhibitors with IC(50) values in the nanomolar range could be identified...
  33. ncbi Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men
    Georg Schatzl
    Department of Urology and Ludwig Boltzmann Institute for Research of Prostate Diseases, University of Vienna, Austria
    Prostate 52:130-8. 2002
    ..The aim of this study was to assess the impact of polymorphisms of three genes within the androgen pathway on prostate volume, clinical parameters, and endocrine status...
  34. ncbi Implementation of the Prostate Cancer Prevention Trial (PCPT)
    Phyllis J Goodman
    Southwest Oncology Group Statistical Center, M S M3 C102, 1100 Fairview Avenue North, Box 19024, Seattle, WA 98109 1024, USA
    Control Clin Trials 25:203-22. 2004
    ..We present an overview of the study design, details of the administrative structure of the study and a description of the successful implementation of the accrual phase...
  35. ncbi Hormonal therapies in acne
    James C Shaw
    Division of Dermatology, Toronto Western Hospital, East Wing 8 517, 399 Bathurst Street, Toronto, Ontario, M5T 2S8, Canada
    Expert Opin Pharmacother 3:865-74. 2002
    ..The main treatments to be discussed are oral contraceptives androgen receptor blockers like spironolactone and flutamide, inhibitors of the enzyme 5 alpha-reductase and topical hormonal treatments...
  36. ncbi Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins
    Hung Huynh
    Laboratory of Molecular Endocrinology, Division of Cellular and Molecular Research, National Cancer Centre of Singapore, Singapore 169610
    Int J Oncol 20:1297-303. 2002
    ....
  37. ncbi A current review of medical therapy for benign prostatic hyperplasia
    Gordon A Brown
    Department of Urology, Kennedy Memorial University Medical Center Hospital, Stratford, NJ, USA
    J Am Osteopath Assoc 104:S11-6. 2004
    ..The authors review the current state of diagnosis of BPH and medical therapy for this condition in the primary care setting...
  38. ncbi Allelic frequencies of six polymorphic markers for risk of prostate cancer
    M L Ribeiro
    Centro de Biologia Molecular e Engenharia Genetica, Universidade Estadual de Campinas, Campinas, SP, Brasil
    Braz J Med Biol Res 35:205-13. 2002
    ..Further studies on prostate cancer patients need to be conducted to assess the significance of these markers in the Brazilian population...
  39. ncbi QSARs for 6-azasteroids as inhibitors of human type 1 5alpha-reductase: prediction of binding affinity and selectivity relative to 3-BHSD
    G A Bakken
    152 Davey Laboratory, Department of Chemistry, The Pennsylvania State University, University Park, PA 16802, USA
    J Chem Inf Comput Sci 41:1255-65. 2001
    ..513 log units (R(2) = 0.89) for the external prediction set. Models are further validated through Monte Carlo experiments in which models are generated after dependent variable values have been scrambled...
  40. ncbi [Use of 5-alpha-reductase inhibitors in the prevention of prostate cancer]
    C Schulman
    Service d Urologie, Cliniques Universitaires de Bruxelles, Hopital Erasme, Route de Lennik 808, B 1070 Bruxelles, Belgique
    Ann Urol (Paris) 38:S35-42. 2004
    ....
  41. ncbi [Effect of selective 5alpha-reductase inhibitor or/and testosterone undecanoate on the reproductive function of male rats]
    Yue Jia
    Department of Endocriology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
    Zhonghua Nan Ke Xue 11:38-41. 2005
    ..To investigate whether 5alpha-reductase inhibitor and dihydrotestosterone (DHT) play a role in spermatogenesis in male rats...
  42. doi Open to debate. The Motion: all men over the age of 50 should be encouraged to take a 5alpha-reductase inhibitor to prevent prostate cancer
    Laurence Koltz
    Eur Urol 53:1079-83. 2008
  43. ncbi Mutations of the androgen receptor coding sequence are infrequent in patients with isolated hypospadias
    A Allera
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75235 8857, USA
    J Clin Endocrinol Metab 80:2697-9. 1995
    ....
  44. ncbi Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia
    Christian R Dolder
    School of Pharmacy, Wingate University, Wingate, NC Pharmacist, NorthEast Medical Center, Concord, NC 28174, USA
    Ann Pharmacother 40:658-65. 2006
    ..To review the pharmacology, pharmacokinetics, efficacy, safety, drug interactions, and dosing recommendations of dutasteride, a 5-alpha reductase inhibitor for benign prostatic hyperplasia (BPH)...
  45. ncbi Synthesis of some new testosterone derivatives fused with substituted pyrazoline ring as promising 5alpha-reductase inhibitors
    Abd El Galil El Sayed Amr
    Applied Organic Chemistry Department, National Research Centre Dokki, Cairo, Egypt
    Acta Pharm 56:203-18. 2006
    ..Pharmacological screening showed that many of these compounds inhibit 5alpha-reductase activity...
  46. ncbi Decreased efficiency of potassium-titanyl-phosphate laser photoselective vaporization prostatectomy with long-term 5 alpha-reductase inhibition therapy: is it true?
    Motoo Araki
    Department of Urology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    Urology 70:927-30. 2007
    ..We evaluate KTP laser PVP as treatment for benign prostatic hyperplasia (BPH) in patients on long-term 5ARIs...
  47. ncbi Different phenotypes in a family with androgen insensitivity caused by the same M780I point mutation in the androgen receptor gene
    P Rodien
    Service d endocrinologie et des maladies de la reproduction, Hopital Bicetre, Le Kremlin Bicetre, France
    J Clin Endocrinol Metab 81:2994-8. 1996
    ..Therefore, the molecular defect of the AR gene may not alone predict the phenotype in families with AI...
  48. ncbi Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride
    Gerald L Andriole
    Division of Urologic Surgery, Washington University, St Louis, Missouri 63110, USA
    J Urol 175:1657-62. 2006
    ..We determined whether the decrease in serum PSA seen with 5alpha-reductase inhibitors affects the clinical usefulness of PSA for prostate cancer screening using data from 2 dutasteride benign prostatic hyperplasia studies...
  49. ncbi The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge
    Gerald Andriole
    Division of Urologic Surgery, School of Medicine, Washington University St Louis, 4960 Children s Place, St Louis, MO 63110, USA
    J Urol 174:2098-104. 2005
    ..However, Gleason score 7-10 tumors were significantly more common in the finasteride vs the placebo group. We considered data on the effects of 5ARIs on prostate cancer natural history and detection...
  50. ncbi Effectiveness of finasteride on patients with male pattern baldness who have different androgen receptor gene polymorphism
    Nagaoki Wakisaka
    NPO Future Medical Laboratory, Tokyo, Japan
    J Investig Dermatol Symp Proc 10:293-4. 2005
    ..Determination of such polymorphism is thought to be useful in the drug choice for MPB patients...
  51. ncbi Different patterns of 5alpha-reductase expression, cellular distribution, and testosterone metabolism in human follicular dermal papilla cells
    Shicheng Liu
    Research Department, Saitama Daiichi Pharmaceutical Co, Ltd, 8 1, Minamisakae cho, Kasukabe, Saitama 344 0057, Japan
    Biochem Biophys Res Commun 368:858-64. 2008
    ..The 5alphaR1 inhibitor MK386 exhibited a more potent inhibitory effect on 5alphaR activity than finasteride (5alphaR2 inhibitor) in bDPCs...
  52. ncbi Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines
    Ann Maria McCrohan
    University College Dublin School of Medicine and Medical Sciences, Mater Misericordiae University Hospital, Dublin, Ireland
    Cancer 106:2743-52. 2006
    ..The objective of the current study was to determine whether dutasteride would induce apoptosis in a range of prostate epithelial cell lines and primary cultures...
  53. ncbi Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes
    Vivian Sobel
    Division of Endocrinology and Metabolism, Department of Medicine, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    J Clin Endocrinol Metab 91:3017-23. 2006
    ..Subjects with complete androgen insensitivity (CAI) and 5alpha-reductase-2 deficiency (5alphaRD-2) are natural human models to study the direct effect of androgens on bone mineral density (BMD)...
  54. ncbi New 5alpha-reductase inhibitors: in vitro and in vivo effects
    Victor Pérez-Ornelas
    Department of Pharmacy, Faculty of Chemistry, National University of Mexico City, Mexico D F, Mexico
    Steroids 70:217-24. 2005
    ..The overall data of this study showed very clearly those compounds 5, 7, 9, 10 are good inhibitors for the 5alpha-reductase enzyme...
  55. ncbi New progesterone derivatives as inhibitors of 5alpha-reductase enzyme and prostate cancer cell growth
    Marisa Cabeza
    Department of Biological Systems and Animal Production, Metropolitan University Xochimilco, Mexico, DF Mexico
    J Enzyme Inhib Med Chem 21:371-8. 2006
    ..Nevertheless steroids 4-7 didn't exhibit any toxic effects in vivo since the animals remained alive during the six days of treatment...
  56. ncbi New dimensions in Hirsutism
    V A Randall
    Department of Biomedical Sciences, University of Bradford, Bradford, B7 1DP, UK
    Lasers Med Sci 21:126-33. 2006
    ..S. Lanigan. Dr. I. Hamzavi concluded the symposium with a presentation of the latest work on eflornithine in combination with laser hair removal. Data were reproduced with the speakers' permission...
  57. ncbi Actions of 5alpha-reductase inhibitors on the epididymis
    Bernard Robaire
    Departments of Pharmacology and Therapeutics and of Obstetrics and Gynecology, McGill University, Montreal, Que, Canada
    Mol Cell Endocrinol 250:190-5. 2006
    ..Mating females to treated males resulted in fewer successful pregnancies and a higher rate of pre-implantation loss. Thus, there may be a role for dual 5alpha-reductase inhibitors as potential components of a male contraceptive...
  58. ncbi Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial
    Carol M Moinpour
    Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center M3 C102, 1100 Fairview Ave North, Box 19024, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 99:1025-35. 2007
    ..The PCPT offered an opportunity to prospectively study the effects of finasteride and other covariates on sexual dysfunction...
  59. ncbi Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate
    A A Yassin
    Clinic of Urology and Andrology, Segeberger Kliniken, Norderstedt, Hamburg, Germany
    Andrologia 39:181-4. 2007
    ..In conclusion, treatment with testosterone undecanoate generates physiological levels of DHT. Prostate safety parameters did not undergo changes...
  60. ncbi Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas
    H Bonkhoff
    Instiute of Pathology, University of the Saarland, Homburg Saar, Germany
    Prostate 29:261-7. 1996
    ..Steroid 5 alpha-reductase is essential for the intracellular accumulation of dihydrotestosterone (DHT), which mediates androgen effects on target tissue...
  61. ncbi Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer
    Nancy Price
    Clin Prostate Cancer 3:211-4. 2005
  62. ncbi Molecular basis of androgen insensitivity
    A O Brinkmann
    Department of Endocrinology and Reproduction, Erasmus University Medical Center Rotterdam, P O Box 1738, 3000 DR Rotterdam, The Netherlands
    Mol Cell Endocrinol 179:105-9. 2001
    ..Differential diagnosis of AIS is possible with syndromes presenting with almost similar phenotypes but with a completely different molecular cause...
  63. ncbi Effects of androgenic-anabolic steroids in athletes
    Fred Hartgens
    Department of Surgery, Outpatient Clinic Sports Medicine, University Hospital Maastricht, and Sports Medicine Center Maastricht, Maastricht, The Netherlands
    Sports Med 34:513-54. 2004
    ..AAS-induced increment of muscle tissue can be attributed to hypertrophy and the formation of new muscle fibres, in which key roles are played by satellite cell number and ultrastructure, androgen receptors and myonuclei...
  64. ncbi A novel missense mutation of 5-alpha reductase type 2 gene (SRD5A2) leads to severe male pseudohermaphroditism in a Turkish family
    Mithat Bahceci
    Department of Endocrinology, University of Dicle, School of Medicine, Diyarbakir, Turkey
    Urology 66:407-10. 2005
    ..To analyze the steroid 5-alpha reductase type 2 gene (SRD5A2) in 2 siblings with severe male pseudohermaphroditism suspected to have 5-alpha reductase deficiency in a Turkish family...
  65. ncbi In vitro androgen-induced growth and morphogenesis of the Wolffian duct within urogenital ridge
    M Tsuji
    Department of Anatomy, University of California, San Francisco 94143
    Endocrinology 128:1805-11. 1991
    ..These data suggest that T is an important hormone in the development of the upper portion of WDs, although it is not possible to exclude a role for DHT in the development of the epididymis...
  66. ncbi Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase activity
    M Takahashi
    MRC Group in Molecular Endocrinology, CHUL Research Centre, Quebec, Canada
    J Steroid Biochem Mol Biol 37:231-6. 1990
    ..5, 1.7 and 2.5 microM, respectively...
  67. ncbi Novel compound heterozygous mutations in the SRD5A2 gene from 46,XY infants with ambiguous external genitalia
    Felipe Vilchis
    Department of Reproductive Biology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Vasco de Quiroga 15, Del Tlalpan, Mexico, DF CP 14000, Mexico
    J Hum Genet 53:401-6. 2008
    ..This further underscores that exon 4 of SRD5A2 may be a site prone to inactivating mutations...
  68. ncbi A review of combination therapy in patients with benign prostatic hyperplasia
    Kevin T McVary
    Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611 3008, USA
    Clin Ther 29:387-98. 2007
    ..The differing mechanisms of action and areas of efficacy of these 2 drug classes make them promising candidates for combination therapy...
  69. ncbi Finasteride delays the onset of maternal behavior in primigravid rats
    Phyllis E Mann
    Department of Biomedical Sciences, Peabody Pavilion, Tufts University, Cummings School of Veterinary Medicine, 200 Westboro Rd, N Grafton, MA 01536, USA
    Physiol Behav 88:333-8. 2006
    ..03). These results suggest that the inhibition of maternal behavior by progesterone during pregnancy is not due to its conversion to allopregnanolone...
  70. pmc Immunohistochemical expression of pi class glutathione S-transferase in the basal cell layer of benign prostate tissue following chronic treatment with finasteride
    R Montironi
    Institute of Pathological Anatomy and Histopathology, School of Medicine, University of Ancona, Ospedale Regionale, Italy
    J Clin Pathol 52:350-4. 1999
    ..Finasteride, a 5-alpha-reductase inhibitor, is used as a chemopreventive agent because it blocks the conversion of testosterone to its byproduct which promotes prostate tumour growth...
  71. ncbi Undervirilization in XY newborns may hide a 5α-reductase deficiency: report of three new SRD5A2 gene mutations
    L Maimoun
    Service d Hormonologie, Hopital Lapeyronie, CHU Montpellier et UMI, Montpellier, France
    Int J Androl 33:841-7. 2010
    ..Early molecular diagnosis is indispensable for the crucial decision of the newborn's sex of rearing...
  72. ncbi The identification of 5 alpha-reductase-2 and 17 beta-hydroxysteroid dehydrogenase-3 gene defects in male pseudohermaphrodites from a Turkish kindred
    S Can
    Department of Medicine, Cornell University Medical College, New York, New York 10021, USA
    J Clin Endocrinol Metab 83:560-9. 1998
    ....
  73. pmc Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia
    Jeannette Lee
    Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Trials 6:628-36. 2009
    ..Two phytotherapies commonly used for BPH are extracts of the fruit of Serenoa repens, the Saw palmetto dwarf palm that grows in the Southeastern US, and extracts of the bark of Pygeum africanum, the African plum tree...
  74. ncbi A class of 4-aza-lithocholic acid-derived haptens for the generation of catalytic antibodies with steroid synthase capabilities
    J Hasserodt
    Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA
    Bioorg Med Chem 8:995-1003. 2000
    ..Surprisingly, an inhibition study showed that the isomer with the inverted configuration at the N-oxide bound more strongly to this catalytic antibody...
  75. ncbi A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride
    P O Gisleskog
    Division of Clinical Pharmacology, GlaxoWellcome Research and Development, Middlesex, England
    Clin Pharmacol Ther 64:636-47. 1998
    ....
  76. ncbi The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing
    J Buelke-Sam
    Lilly Research Laboratories, A Division of Eli Lilly and Company, Greenfield, Indiana 46140, USA
    Reprod Toxicol 12:217-21. 1998
    ....
  77. ncbi Aromatization mediates aggressive behavior in quail
    B A Schlinger
    Department of Psychology, University of California, Los Angeles 90024
    Gen Comp Endocrinol 79:39-53. 1990
    ....
  78. ncbi [Primary amenorrhea and XY karyotype: identifying patients in risk]
    Rafael Fabiano Machado Rosa
    Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil
    Rev Bras Ginecol Obstet 30:566-72. 2008
    ..to verify the prevalence and clinical characteristics of patients with primary amenorrhea and XY karyotype, evaluated in our Service, aiming at identifying findings which could help their recognition...
  79. ncbi Content of 5-alpha-reductase (type 1 and type 2) mRNA in dermal papillae from the lower abdominal region in women with hirsutism
    P Skałba
    Department of Gynaecological Endocrinology, Medical University of Silesia, Katowice, Poland
    Clin Exp Dermatol 31:564-70. 2006
    ..The male distribution pattern of terminal hair in females is termed hirsutism. It is most common among women with hyperandrogenism; however, it may also affect patients with normal androgen levels (idiopathic hirsutism)...
  80. ncbi Big head? Bald head! Skull expansion: alternative model for the primary mechanism of AGA
    Paul J Taylor
    Orpington, Kent BR6 6LH, United Kingdom
    Med Hypotheses 72:23-8. 2009
    ..A redirection of genetic research towards the identification of those genes responsible for skull shape and development would be appropriate, and may reveal the genetic connection to AGA including its paternal link...
  81. ncbi Disease versus disease: how one disease may ameliorate another
    E Richard Stiehm
    Department of Pediatrics, Mattel Children s Hospital, UCLA, Los Angeles, California 90095, USA
    Pediatrics 117:184-91. 2006
    ..Additional exploration of these genetic, infectious, and metabolic influences on disease severity may provide new therapeutic approaches to HIV and other diseases...
  82. ncbi Endothelin-1 as a luteinization inhibitor: inhibition of rat granulosa cell progesterone accumulation via selective modulation of key steroidogenic steps affecting both progesterone formation and degradation
    C Tedeschi
    University of Maryland School of Medicine, Department of Obstetrics Gynecology, Baltimore
    Endocrinology 131:2476-8. 1992
    ....
  83. ncbi Pharmacotherapy strategies in chronic prostatitis/chronic pelvic pain syndrome management
    Adam B Murphy
    Northwestern University Feinberg School of Medicine, Department of Urology, 303 E Chicago Avenue, Chicago, IL 60611, USA
    Expert Opin Pharmacother 11:1255-61. 2010
    ..The syndrome is variable in presentation and symptom management and efficacy will vary between inflicted men...
  84. ncbi Bacterial metabolism of natural and synthetic sex hormones undergoing enterohepatic circulation
    J Winter
    St Luke s Roosevelt Institute for Health Sciences, New York, NY 10025
    J Steroid Biochem 27:1145-9. 1987
    ..The enzymes can also be used for titration of specific bacterial strains in fecal flora and as markers for bacterial identification in particular for the strains difficult to be defined by regular biochemical reactions...
  85. ncbi 5 alpha-reductase-2 gene mutations in the Dominican Republic
    L Q Cai
    Department of Medicine, New York Hospital Cornell University Medical College, New York 10021, USA
    J Clin Endocrinol Metab 81:1730-5. 1996
    ..Thus, the identification of multiple mutations in the 5 alpha-reductase-2 gene in male pseudohermaphrodites from the Dominican Republic demonstrates a lack of common ancestry, as had been previously postulated...
  86. ncbi 5 alpha-reductase activity in epithelium and stroma of prostates from intact and castrated dogs treated with androstenedione, the aromatase inhibitor 1-methyl-1,4-androstadiene-3,17-dione, and cyproterone acetate
    S Tunn
    Institute of Clinical Chemistry, University Clinic Bergmannsheil Bochum, Federal Republic of Germany
    Prostate 12:243-53. 1988
    ..4) In groups I, III, and IV the proportion of epithelial 5 alpha-reductase was rather low. These data were discussed in the light of the histological findings...
  87. ncbi The valine allele of the V89L polymorphism in the 5-alpha-reductase gene confers a reduced risk for hypospadias
    Hanh T T Thai
    Department of Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
    J Clin Endocrinol Metab 90:6695-8. 2005
    ..Hypospadias is one of the most common malformations in man, with an incidence of 1:300 in newborn boys. No gene has been identified that causes isolated hypospadias, but the androgenic influence is important during male genital development...
  88. ncbi Aromatase, steroid-5-alpha-reductase type 1 and type 2 mRNA expression in gonads and in brain of Xenopus laevis during ontogeny
    R Urbatzka
    Department of Inland Fisheries, Leibniz Institute of Freshwater Ecology and Inland Fisheries, Müggelseedamm 310, 12587 Berlin, Germany
    Gen Comp Endocrinol 153:280-8. 2007
    ..Especially in gonads Srd5a2 seems to be important for physiological regulation of testis development while Aro is associated with the development of ovaries...
  89. ncbi Etiologic classification of severe hypospadias: implications for prognosis and management
    N Albers
    Department of Pediatrics, University of Bonn, Germany
    J Pediatr 131:386-92. 1997
    ..Classification of severe hypospadias employing a broad array of diagnostic tools. Standardization of a diagnostic approach to children with hypospadias. Indentification of patients at risk of having malignancies and endocrine problems...
  90. ncbi Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action
    Mario A Eisenberger
    Johns Hopkins Medical Institutions, Baltimore, Maryland 21231 1000, USA
    Urology 63:114-9. 2004
    ..To study the safety, pharmacokinetics, biologic activity, and preliminary efficacy of the bispecific 5-alpha-reductase inhibitor (LY320236) in prostate cancer...
  91. ncbi [Diagnostic and therapeutic management of the benign prostatic hyperplasia by the general practitioners in the Maine-et-Loire]
    P Bigot
    Service d Urologie, CHU d Angers, Universite d Angers, Angers, France
    Prog Urol 20:65-70. 2010
    ..To assess the diagnosis and therapeutic management of the benign prostatic hyperplasia (BPH) by the general practitioners (GPs) in the Maine-et-Loire...
  92. pmc Isolated micropenis reveals partial androgen insensitivity syndrome confirmed by molecular analysis
    Amrit Bhangoo
    Pediatric Endocrinology Division of Maimonides Infants and Children s Hospital of Brooklyn, Children s Hospital at SUNY Downstate, Brooklyn, NY 11219, USA
    Asian J Androl 12:561-6. 2010
    ..This underlines the importance of including AR gene analysis in the evaluation of isolated micropenis with normal plasma T to ensure proper management of the patient and appropriate genetic counseling for the family...
  93. ncbi The human sebocyte culture model provides new insights into development and management of seborrhoea and acne
    C C Zouboulis
    Department of Dermatology, University Medical Center Benjamin Franklin, Free University of Berlin, Germany
    Dermatology 196:21-31. 1998
    ....
  94. ncbi New therapeutic approaches for epilepsies, focusing on reorganization of the GABAA receptor subunits by neurosteroids
    Yoshiya L Murashima
    Graduate School of Human Health Science, Tokyo Metropolitan University, Tokyo, Japan
    Epilepsia 51:131-4. 2010
    ..Therefore, GABAA receptor-regulating neurosteroids may be a promising target for the development of novel antiepileptic agents...
  95. ncbi Medical therapy and quality of life
    C R Chapple
    Department of Urology, Royal Hallamshire Hospital, Sheffield, UK
    Eur Urol 34:10-7; discussion 46. 1998
    ..These documented properties of the alpha 1A-adrenoceptor antagonists make them an ideal choice for the medical treatment of symptomatic BPH...
  96. ncbi Benign prostatic hyperplasia. Practical treatment guidelines
    T Tammela
    Division of Urology, Tampere University Hospital, Finland
    Drugs Aging 10:349-66. 1997
    ..The final decision about the best treatment for a particular patient must take into account the patient's preference after he has been informed of the different options...
  97. ncbi Assessment of porcine and human 16-ene-synthase, a third activity of P450c17, in the formation of an androstenol precursor. Role of recombinant cytochrome b5 and P450 reductase
    Penny Soucy
    Molecular Endocrinology and Oncology Research Center, Laval University Medical Center CHUL and Laval University, Quebec, Canada
    Eur J Biochem 270:1349-55. 2003
    ..Our results therefore demonstrate that human P450c17, as other enzymes of the classical steroidogenic pathway, is involved in the biosynthetic pathway leading to the formation of androstenol...
  98. ncbi Progesterone is extensively metabolized in osteoblasts: implications for progesterone action on bone
    M Quinkler
    Clinical Endocrinology, Internal Medicine, Center for Gastroenterology, Hepatology and Endocrinology, Charite Campus Mitte, Charite University Medicine Berlin, Chariteplatz 1, Berlin, Germany
    Horm Metab Res 40:679-84. 2008
    ..Conversely, osteoblasts have the capacity to convert progestogens to metabolites reported to have anabolic actions through the estrogen receptor...
  99. ncbi A putative 5 alpha-reductase inhibitor demasculinizes portions of the zebra finch song system
    W Grisham
    Department of Physiological Science, University of California, Los Angeles 90095 1527, USA
    Brain Res 750:122-8. 1997
    ..Regardless of the reason(s) for differential effects on the sexually dimorphic characteristics of the song system, the data clearly suggest that steroid hormones play a role in the normal masculine development of the song system...
  100. ncbi A new deletion of the 5 alpha-reductase type 2 gene in a Turkish family with 5 alpha-reductase deficiency
    C Boudon
    Centre de Recherches de l Institut National de la Santé et de la Recherche Médicale, INSERM, Montpellier, France
    Clin Endocrinol (Oxf) 43:183-8. 1995
    ..The molecular basis for male pseudohermaphroditism produced by the 5 alpha-reductase deficiency is becoming increasingly understood...
  101. ncbi Steroidogenesis in interstitial cells and microsomal fraction of immature pig testes
    G M Cooke
    Department d anatomie et physiologie animale, , , St Hyacinthe, , Canada
    J Reprod Fertil 91:175-85. 1991
    ..The relative magnitudes of these populations indicate that most of the steroidogenic enzymes in the interstitial cells are not involved in the normal response to trophic stimulation...

Research Grants62

  1. Chemoprevention of Prostate Cancer
    SUSAN AUDREY HALL; Fiscal Year: 2012
    ..The public health relevance of the proposal is substantial given the common occurrence of prCA and the urgent need for more information regarding high-grade prCAs and breast cancers potentially caused by 5-ARIs. ..
  2. Equol and Regulation of Prostate Growth
    Robert J Handa; Fiscal Year: 2011
    ..The long-term goal of this project is to define the mechanism by which equol acts to inhibit the pathological growth of the prostate gland ..
  3. Axon, Testosterone and Mental Health during Adolescence
    Tomas Paus; Fiscal Year: 2013
    ....
  4. Reduced Levels of 5-alpha Reductase 2 in Adult Prostate Tissue and BPH Therapy
    Aria F Olumi; Fiscal Year: 2013
    ..Recognition of mechanisms that regulate expression of 5-1 reductase 2 will lead to identification of newer compounds and better targeted therapies for BPH and reduce the rates of invasive therapies for this benign condition. ..
  5. Clinical validity and utility of genomic targeted chemoprevention of PCa
    Jianfeng Xu; Fiscal Year: 2010
    ..This would lead to a significant decrease in prostate cancer diagnoses and greatly reduce the burden to the individual and society. ..
  6. Hormonal and molecular consequences of androgen replacement on the prostate
    Stephanie T Page; Fiscal Year: 2010
    ..Nelson, MD, Associate Professor of Medicine (Oncology), University of Washington School of Medicine will co-mentor this award. ..
  7. Role of 5-alpha Reductase in Testosterone Actions
    Shalendar Bhasin; Fiscal Year: 2007
    ..abstract_text> ..
  8. MOLECULAR EPIDEMIOLOGY OF BIRTH DEFECTS
    Jeanne Manson; Fiscal Year: 2001
    ..The research proposal is an extension of the training component and exemplifies how molecular, genetic and epidemiologic approaches can be combined to study the etiology of birth defects. ..
  9. CHLORINATED HYDROCARBONS EFFECTS ON MAMMALIAN SYSTEMS
    David Kupfer; Fiscal Year: 2003
    ..CYP3A4 catalyzes the metabolism of the majority of drugs and is involved in drug-drug interaction. Understanding the mechanism of 3A4 activity would be useful in predicting drug interactions and drug:drug-metabolite interactions. ..
  10. BPH AND PROSTATE CA IN 5A-REDUCTASE-2 DEFICIENT CARRIERS
    Julianne Imperato McGinley; Fiscal Year: 2000
    ..Studies will also continue on male pseudohermaphrodites who are homozygous for the 5-alpha-reductase-2 gene, as it pertains to prostate size, PSA determination and secondary sexual hair distribution. ..
  11. STEROID 5 ALPHA REDUCTASE--STRUCTURE/FUNCTION
    Shutsung Liao; Fiscal Year: 2000
    ..A recently developed photoaffinity-label will be used to identify amino acid residues in the steroid-binding domain of the isozymes. ..
  12. MEDICAL THERAPY IN BENIGN PROSTATIC HYPERPLASIA
    Michael Lieber; Fiscal Year: 2001
    ....
  13. GONADAL AND PHENOTYPIC SEX DIFFERENTIATION
    FREDRICK GEORGE; Fiscal Year: 1993
    ..A transplantation model will be developed to study the possible role of estrogen in urogenital tract development...
  14. TESTOSTERONE EFFECTS ON GONADOTROPINS AND LIPIDS IN MEN
    CARRIE BAGATELL; Fiscal Year: 1992
    ..This knowledge may in turn be useful in developing new treatment options for diseases of the male reproductive system and in developing strategies to decrease coronary risk from lipoprotein abnormalities...
  15. ANDROGENS REGULATE IGF PATHWAY AND PROSTATE DISEASES
    Julianne Imperato McGinley; Fiscal Year: 2001
    ..B) Prostatic cancer cells treated with either control vehicle, testosterone, DHT, testosterone plus 5alpha-reductase inhibitors, and DHT plus 50:-reductase inhibitors. ..
  16. Formulated Phytosterols - A New Treatment For Benign Prostatic Hyperplasia
    CURTIS SPILBURG; Fiscal Year: 2006
    ..Because of the acknowledged safety of plant sterols, the proposed product will be cost effective, free of side effects and available over the counter. [unreadable] [unreadable] [unreadable]..
  17. Allium Compounds in Control of Human Prostate Cancer
    JOHN PINTO; Fiscal Year: 2003
    ....
  18. MEDICAL THERAPY FOR BPH--DATA COORDINATING CENTER
    PAMELA BURROWS; Fiscal Year: 2001
    ....
  19. PORT-II FOR PROSTATIC DISEASES
    Michael Barry; Fiscal Year: 1999
    ....
  20. METABOLISM & CONTROL OF TESTOSTERONE ANDROGENS IN MAN
    Richard Horton; Fiscal Year: 1990
    ..R. Lobo and R. Marrs we shall test whether skin minses and fibroblasts in culture synthesize 3 alpha diol G in vitro and whether formation parallels 5 alpha reductase activity in men, women, and in hirsute states...
  21. Inhibitors of 5alpha-reductase for acne therapy
    Lingna Li; Fiscal Year: 2002
    ..PROPOSED COMMERCIAL APPLICATIONS: Liposomal 4-MA will be developed as a topical selectively targeted therapeutic for acne for which they should be a very market. ..
  22. 5 ALPHA REDUCTASE GENOTYPE, RACE PROSTATE CANCER RISK
    Laurence Kedes; Fiscal Year: 2003
    ....
  23. Vascular Targeting for Imaging and Treatment of Benign Prostatic Hyperplasia
    Michael Zwick; Fiscal Year: 2009
    ....
  24. FACTORS INFLUENCING TESTICULAR DESCENT
    FREDRICK GEORGE; Fiscal Year: 1992
    ..If homogeneous cell strains can be established from gubernacular tissues, then the effects of androgens on cell proliferation and differentiation will be examined...
  25. MALE PSEUDOHERMAPHRODITISM--THE BIOLOGY OF ANDROGENS
    Julianne Imperato McGinley; Fiscal Year: 1992
    ....
  26. 5 ALPHA-REDUCTASE IN THE PRIMATE EPIDIDYMIS
    MARY MAHONY; Fiscal Year: 1999
    ..The proposed hypothesis is: activin and inhibin, by opposing actions and in concert with androgens, modulate 5alpha-reductase gene expression in the primate proximal caput epididymis with minimal effect on the more distal corpus region. ..
  27. Saw Palmetto Use and Risk of Prostate Cancer
    I Min Lee; Fiscal Year: 2004
    ..abstract_text> ..
  28. ENDOGENOUS SEX HORMONES, GENETICS, AND PROSTATE CANCER
    Chu Chen; Fiscal Year: 2001
    ..abstract_text> ..
  29. ENDOCRINE ROLES OF STEROID 5 ALPHA REDUCTASE ISOZYMES
    David Russell; Fiscal Year: 2003
    ....
  30. EFFECT OF MAMMARY TUMORS ON STEROID METABOLISM
    YUSUF ABUL HAJJ; Fiscal Year: 1980
    ..The effect of surgical removal of tumor and cell-free tumor extract administration will be studied in order to determine whether the tumor contains a factor(s) responsible for altered steroid metabolism...
  31. Androgen Pathway and Genetic Risk of Prostate Cancer
    Noel Weiss; Fiscal Year: 2002
    ..The identification and confirmation of high-risk genetic profiles for prostate cancer could enable better screening and potential preventive interventions aimed at the gene products. ..
  32. Hormonal Control of SBMA Pathogenesis
    Diane Merry; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  33. Control of Prostate Cancer: Botanical/Drug Interactions
    Shutsung Liao; Fiscal Year: 2003
    ....
  34. MEDICAL THERAPY OF PROSTATIC SYMPTOMS (MTOPS)
    E Crawford; Fiscal Year: 2001
    ..Adherence strategies, critical to the ultimate success and complete evaluation of trial results, include behavioral, social, and educational interventions. ..
  35. NIA ACADEMIC AWARD--ANDROGEN ACTION IN THE ELDERLY MALE
    JOYCE TENOVER; Fiscal Year: 1992
    ..This research will give important information about the contribution of DHT to steroid negative feedback regulation of LHRH secretion that could be applicable to man...
  36. ANDROGEN EFFECTS ON OVULATION AND FOLLICULAR ATRESIA
    Virendra Mahesh; Fiscal Year: 1980
    ..It will also be examined if androgen induced follicular atresia can be prevented by stimulation of granulosa cell aromatase activity by FSH. ..
  37. PROSTATE CANCER IN MEXICANS AMERICANS & AFRICAN AMERICAN
    Sara Strom; Fiscal Year: 2003
    ..Understanding how genetic predisposition and exogenous exposures interact to determine prostate cancer susceptibility will allow the development of more effective ethnic-specific prevention strategies. ..
  38. IN VITRO PRESCREENING OF CLASSES OF CHEMOPREVENTIVES
    JOHN PEZZUTO; Fiscal Year: 1999
    ..There are ten agents in each mechanistic category to assay and to determine dose-related effects. ..
  39. Excessive Alcohol Intake Induced By Withdrawal
    Deborah Finn; Fiscal Year: 2005
    ..Not only will this information help in furthering our understanding of the interaction between ethanol intake and withdrawal, but it also would aid in the development of new strategies for the treatment of alcoholism. ..
  40. The Efficacy of TUMT and Neoadjuvant Finasteride for BPH
    Kevin McVary; Fiscal Year: 2005
    ..We are proposing a 3-arm, placebo/sham controlled, randomized clinical trial using changes in symptoms as the primary ..
  41. N O S AND NEUROPATHIC AND ENDOTHELIAL INDUCED ED
    Kevin McVary; Fiscal Year: 2002
    ..Results of this research will aid in the understanding of how diabetic neuropathy contributes to sexual dysfunction and elucidate possible mechanisms to prevent them. ..
  42. REGULATION OF PROSTATE GROWTH BY NEURAL FACTORS
    Kevin McVary; Fiscal Year: 2001
    ..Using this model allows one to explore the limits of understanding prostatic neuroregulation, to explore neurotrophic influences on exocrine gland development, and to possibly uncover novel methods to influence prostate disease. ..
  43. PHYSICIAN AND SCIENTIST TRAINING IN UROLOGICAL RESEARCH
    Alan Wein; Fiscal Year: 2007
    ..Funding is sought for two years of support for three trainees annually. ..
  44. Analytical Reconstruction of Feedback Signaling in Aging Men
    Johannes Veldhuis; Fiscal Year: 2008
    ..The present proposal develops a general biomathematical framework for dissecting otherwise observed pathways that control hormone output in aging, stress and disease. [unreadable] [unreadable] [unreadable]..
  45. Systematic Reviews in Urologic Diseases
    Timothy Wilt; Fiscal Year: 2008
    ..This will provide rapid dissemination, enhances implementation, and identifies new areas requiring additional research. ..
  46. The Effects of Neuroactive Steroids on Acute Ethanol Withdrawal in Mice
    KATHERINE GILILLAND; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  47. Mechanistic bases for age-related androgen deficiency
    Johannes Veldhuis; Fiscal Year: 2007
    ..Knowing why testosterone falls should help foster new and safer ways to prevent the problem. [unreadable] [unreadable] [unreadable]..
  48. Chronic Prostatitis Collaborative Research Network CPCRN
    J Nickel; Fiscal Year: 2007
    ..Nickel as PI has the experience, expertise and the proven ability to design, implement and enroll patients with CPPS in clinical studies and will be a valuable partner in the proposed CPCRN and UCPPSCG. ..
  49. Interstitial Cystitis Clinical Research Network (ICCRN)
    J Nickel; Fiscal Year: 2007
    ..site with Dr. Nickel as PI has the experience, expertise and the proven ability to design, implement and enroll patients with IC in clinical strudies and will be a valuable partner in the proposed ICCRN and UCPPSCG. ..
  50. Ensemble Disruption of the GnRH-LH-Testosterone Axis
    Johannes Veldhuis; Fiscal Year: 2007
    ..Expected corollary outcomes are enhanced diagnosis, assessment and management of more subtle pathophysiology of the male gonadal axis in puberty and adulthood. ..
  51. TRAINING IN UROLOGY
    Alan Wein; Fiscal Year: 2003
    ..At each step the trainees will be advised by experienced investigators. It is expected that in return the clinician's will offer to the laboratory insight into the fundamental clinical problems facing the specialty of urology. ..
  52. Trainee-Focusted Training for Research Integrity
    Steven Jacobsen; Fiscal Year: 2003
    ..6. Identify high frequency perceptions or frames of reference, which are substantially at odds with accepted research norms and begin designing better interventions to alter them. ..
  53. CHARACTERIZATION & TREATMENT OF CATEGORY III PROSTATITIS
    J Nickel; Fiscal Year: 2003
    ..Results from this 3 part study will be analyzed and correlated between groups and within groups, both concurrently and sequentially. ..
  54. Prostate Cancer Development & Growth
    Christina Wang; Fiscal Year: 2004
    ..The results will provide the important missing link between diet fat and CaP growth and development. ..
  55. ENSEMBLE MODEL OF STRESS ACTH-ADRENAL AXIS
    Johannes Veldhuis; Fiscal Year: 2005
    ....
  56. Neurosteroid Modulation of Ethanol Intake and Reward
    Matthew Ford; Fiscal Year: 2004
    ..Results from these experiments will provide valuable insights into the mechanisms underlying neurosteroid modulation of ethanol intake and reward. ..
  57. THE AGING GH AXIS IN POSTMENOPAUSAL WOMEN
    Johannes Veldhuis; Fiscal Year: 2005
    ..An enhanced knowledge base should aid ultimately in formulating more innovative preventive and interventional strategies to limit hyposomatotropism in older and/or estrogen-deficient humans. ..
  58. MOLECULAR BASIS OF SEX STEROID ACTION IN PROSTATE CANCER
    Yuan Shan Zhu; Fiscal Year: 2005
    ..abstract_text> ..
  59. Primary Care Colorectal Ca Screening Surveillance System
    Richard Hoffman; Fiscal Year: 2005
    ..abstract_text> ..
  60. Harbor-UCLA Initiative for Minority Student Development
    Christina Wang; Fiscal Year: 2005
    ....
  61. COMPARISON OF TREATMENT EFFICACY FOR PROSTATE CANCER
    Peter Albertsen; Fiscal Year: 2002
    ....